Home » Topics » Disease categories and therapies » Cardiovascular

Cardiovascular
RSS

Solvay launches Aceon tablets in the U.S. for 24-hour control of hypertension

Oct. 8, 1999

Newly discovered complement inhibitor optioned by ZymoGenetics

Oct. 7, 1999

ETA antagonist TBC-2576 is active in rat model of pulmonary hypertension

Oct. 7, 1999

FDA approves Pfizer's Tikosyn

Oct. 6, 1999

New cardiovascular agents from Yamanouchi block If current

Oct. 6, 1999

Preparation and use of dual ETA/ETB antagonists disclosed by BASF

Oct. 5, 1999

Adenosine-dependent cardioprotective effect demonstrated for MX-68

Oct. 5, 1999

Dual NEP and ECE inhibitors from Solvay potentially useful in cardiac insufficiency

Oct. 1, 1999

Antiischemic NHE-1 inhibitors synthesized at Pfizer

Oct. 1, 1999

Sildenafil in pulmonary hypertension and heart failure

Oct. 1, 1999

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 21, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 21, 2026.
Cell/gene therapy sector now sustainable; China competition mounting
BioWorld
There was an upbeat message for cell and gene therapy companies in the 2026 industry update presented as the J.P. Morgan Healthcare Conference opened on Monday,...
Abbvie snags PD-1/VEGF bispecific in potential $5B Remegen deal
BioWorld
With rumors regarding a couple of potential mega-mergers making the rounds, the week of the annual J.P. Morgan Healthcare Conference kicked off with the official...
Neurotrimin unveiled as marker in intellectual disability
BioWorld Science
Neurotrimin (NTM) is a member of the IgLON family, the disruption of which has been tied to emotional learning deficits and anxiety-like behavior in animal...